Brief Report: CD14bright CD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy

Chelsey J. Judge, Johan K. Sandberg, Nicholas T. Funderburg, Kenneth E. Sherman, Adeel A. Butt, Minhee Kang, Alan L. Landay, Michael M. Lederman, Donald D. Anthony

Research output: Contribution to journalArticlepeer-review

Abstract

During HIV+ hepatitis C virus (HCV)+ coinfection CD14 bright CD16 - monocytes produce soluble immune-activation markers that predict disease progression and poor response to interferon (IFN)-α treatment. We evaluated relationships among immune activation, monocyte phenotype, CD4-memory T cells, and HCV-, cytomegalovirus-, and cytomegalovirus/Epstein-Barr virus/influenza-specific IFN-γ-response before and during IFN-α treatment. Effector-memory and central-memory CD4 T-cell frequencies were lower in HCV+ HIV+ donors than in uninfected donors and correlated negatively with HCV level, CD14 bright CD16 - monocytes, and plasma sCD14. sCD14 and CD14 bright CD16 - monocytes negatively correlated with IFN-α-dependent HCV decline. CD4 effector-memory T cells positively associated with cytomegalovirus/Epstein-Barr virus/influenza(CEF)-specific IFN-γ response, while sCD14 negatively associated with both CD4 effector-memory T cells and CEF-specific IFN-γ response. These data support a role for memory-CD4 T cells in HCV containment and link immune activation and CD14 bright CD16 - -monocyte frequency to the failure of IFN-dependent HCV clearance.

Original languageEnglish (US)
Pages (from-to)258-262
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume73
Issue number3
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Keywords

  • CMV
  • HIV
  • T cell
  • cellular immunity
  • hepatitis C
  • monocyte

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Brief Report: CD14bright CD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy'. Together they form a unique fingerprint.

Cite this